Skip to content

Cronos Group

US · CRON #3133 by market cap Listed 1970
3.04 -0.04 -1.30%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 1.16 Expensive vs history 98th percentile
5-year average 0.83 · #29 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 21.13 Expensive vs history 88th percentile
5-year average -4.51 · forward 16.39 · #12 of 26 in Drug Manufacturers - Specialty & Generic
P/S ratio 6.01 Cheap vs history 4th percentile
5-year average 9.83 · forward 4.46 · #60 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Cronos Group (CRON) 1.11B 19.00 1.04 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value3.96 Economic moatNone UncertaintyMedium

Trading 30.3% below Morningstar's fair value estimate.

Fair value

Cronos Group Inc is assigned a 4-star quantitative star rating, indicating our belief that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 15% discount to our quantitative fair value estimate of $3.96 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 80.8%, which lies in the top 40% compared with peers globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The firm's solid growth is an additional encouraging factor. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's revenue 3-year growth of 36.7%, for example, ranks in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which further promotes our favorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.

Cronos Group discussion 0 comments

Add a comment